<DOC>
	<DOCNO>NCT00003551</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness aminocamptothecin treat patient stage III , stage IV , recurrent kidney cancer .</brief_summary>
	<brief_title>Aminocamptothecin Treating Patients With Advanced Recurrent Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , survival patient advance renal cell carcinoma treat aminocamptothecin colloidal dispersion . II . Determine nature degree toxicity aminocamptothecin patient population . OUTLINE : Patients receive aminocamptothecin colloidal dispersion intravenously 120 hour weekly 2 week follow 1 week rest . Courses repeat every 3 week absence disease progression dose limit toxicity . Patients follow every 3 month first 2 year , every 6 month next 3 year , yearly thereafter . PROJECTED ACCRUAL : A total 10-29 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III , stage IV , recurrent renal cell carcinoma Measurable disease No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1500/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL ALT AST great 2.5 time institutional normal value Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled systemic infection No prior concurrent malignancy except nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ breast curatively treat No evidence delirium , confusion , suicidal ideation , untreated depression PRIOR CONCURRENT THERAPY : Biologic therapy : At least 30 day since prior cytokine recover No 1 prior treatment cytokine ( interleukin2 interferon ) Chemotherapy : No prior cytotoxic chemotherapy No prior aminocamptothecin No concurrent antineoplastic agent Endocrine therapy : At least 30 day since prior hormone therapy recover No 1 prior hormone therapy ( tamoxifen medroxyprogesterone ) Radiotherapy : Prior radiotherapy allow indicator lesion great 15 % marrow produce bone irradiate Surgery : Recovered prior surgery Other : At least 30 day since investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>